Abstract: Calmodulin plays a role in several life processes, its flexibility allows binding of a number of different ligands from small molecules to amphiphilic peptide helices and proteins. Through the diversity of its functions, it is quite difficult to find new drugs, which bind to calmodulin as a target. We present available structural information on the protein, obtained by X-ray diffraction, nuclear magnetic resonance spectroscopy and molecular modeling and try to derive some conclusions on structureactivity relationships.
INTRODUCTION
Calmodulin (CaM) is the primary Ca 2+ signaling protein in eukaryotic biology. It is ubiquitous and 100%
conserved among vertebrates [1, 2] . Higher eukaryotes, including humans, possess three distinct bona fide CaM genes differentially regulated, encoding the identical protein [3, 4] . CaM is a small, 148 amino acid protein and is highly acidic, with a pI of approximately 4.6 [5] . The structure of CaM consists of homologous N-and C-terminal domains linked together by a flexible tether, usually referred to as the "central linker" [6] . Within each terminal lobes, there are two Ca 2+ -binding "EF-hand" motifs flanked by tightly structured domains [7] . Upon binding Ca 2+ ions, extensive hydrophobic surfaces become exposed to the solvent, promoting the interaction of CaM with target proteins. The flexibility of the CaM molecule facilitates its binding to diverse array of targets, including more than 100 proteins important for Ca 2+ -dependent intracellular signaling. CaM is the mediator of such diverse biological processes as muscle contraction, fertilization, cell proliferation, vesicular fusion, and apoptosis [8] . Because of its involvement in so many vital processes, deletion of the CaM gene is lethal [9] . One of the few unifying characteristics of the CaM binding sequences is the ability of all to form basic, amphiphilic helices when complexed with CaM [10] .
Small, hydrophobic molecules also bind to CaM and modify its function by inhibiting, or modifying the interaction with other proteins [11] [12] [13] [14] [15] [16] [17] [18] . Some of these compounds used as pharmacological agents to block CaMmediated enzyme activation may act as antipsychotics, muscle relaxants, antidepressants, minor tranquilizers, and local anesthetics [19, 20] . CaM antagonists (such as trifluoperazine [TFP] and many others) are also being evaluated for the treatment of cancers that are both sensitive and resistant to conventional anticancer drugs [21] [22] [23] .
In Ca 2+ -free, or apo-CaM, the structure of both terminal domains is defined by two helix-loop-helix motifs called EF-hands, connected by short, slightly distorted beta sheets. Although the two domains share 46% sequence identity and highly similar globular folds in the absence of Ca
2+
, the C-terminal lobe is in dynamic equilibrium between its closed and semi-open conformation while the N-terminal domain remains closed [24, 25] . This means that the hydrophobic amino acids of the domains are shielded from the solvent. The central linker of the protein (residues 65 -92) is extremely flexible in solution, especially near its midpoint, resulting in the two domains tumbling independently of one-another [6, [26] [27] [28] (see Fig. (1) ). -loaded form (pdb code: 1cll [29] ). Homologous N-and C-terminal regions are colored black, the central linker is gray. Ca 2+ ions are shown as dark grey spheres. Ca 2+ -binding by ligand-free CaM takes place in sequential steps, first to the C-and then to the N-lobe. Ca 2+ binding causes a change in the overall shape of the molecule from a globular ellipsoid to a dumbbell shape, and induces characteristic changes within the terminal domains too. The two terminal domains rotate outward and their separation increases. The central linker remains highly flexible in solution [6] while forms a helix in the crystal structure [29] (see Fig. (1) ). The solution structures reflect a more compact overall shape, with smaller radius of gyration [30, 31] . Molecular dynamics studies also indicate that the central linker is unlikely to form a helical structure in solution, and behaves like a flexible tether connecting the terminal lobes [32, 33] . The domains rigidify upon Ca 2+ binding and the helix pairs of the EF-motifs reorient with respect to each other. This causes a significant change, opening deep hydrophobic patches within the lobes (see Fig. (2) ). CaM contains Met side chains in unusually high abundance, accounting for nearly half of the hydrophobic surface of each patch [11] . These methionines were shown to become solvent exposed in the open conformation of CaM [35, 36] , and are essential for CaM's ability to accommodate such different ligands [37, 38] (see Fig. (3) ). Met side chains are highly pliable [36, 39] , and they are ideal for creating favorable van der Waals interactions due to the polarizability of sulfur and are at the same time fairly compatible with the surrounding aqueous medium [38, 40] .
Ca
2+ -CaM is therefore equipped with flexible, dynamic and highly attractive hydrophobic binding surfaces on each lobe [5] . 
CALMODULIN AND ITS TARGETS
A number of different mechanisms of how CaM activates its target proteins have been described [1] .
"Auto-inhibitory domain activation" is a process where CaM binding displaces the substrate-imitating autoinhibitory domain of the protein from the active site by wrapping around it and diminishing its contacts with the catalytic region. In these complexes the overall structure of CaM is globular, the central linker is significantly bent.
In most cases the protein recognizes sequence motifs classified as the 1-10, 1-14 or 1-16 motif which stand for the target carrying two, preferentially bulky residues separated by 8 or 12 or 14 amino acid residues, and their subsets, such as the 1-5-10 or the 1-8-14, and 1-5-8-14 motif, where three or more hydrophobic residues define the binding sequence. [41] . CaM dependent Ser/Thr kinases such as CaM kinase I/II/IV, CaM kinase kinase, myosin light chain kinase, as well as cerebral nitric oxide synthase, plasma membrane Ca 2+ pumps and the N-methyl-D-aspartate (NMDA) receptor belong to this group. Based on the comparison of 17 such compact structures the concept of FLMM cavities was derived, where the letters stand for the one letter codes of Phe19, Leu32, Met51, Met71 of the N-terminal hydrophobic patch, and Phe92, Leu105, Met124, Met144 of that of the C-terminal domain [42] . These hydrophobic patches typically accommodate Phe, Trp or Tyr residues of the target, although the less specific Nterminal FLMM N shows greater variability (see Fig. (4) ). Antagonist binding can also be described in terms of FLMM binding pockets, since trifluoroperazin, the most studied inhibitor of CaM (see below), binds to both FLMM cavities. From the crystal structures of complexes belonging to this group the following CaM residues can be seen in close contact (nonhydrogen atoms within 3.5 Ǻ) with target sequences: one or two of the three acidic residues of the N terminal sequence Glu7/Glu11/Glu14, Glu84 or Glu87 of the central linker, Glu114 or Glu127 of the C-terminal domain, along with one or two of the terminal methionines Met124/Met144/ Met145.
Calcineurin is a Ser/Thr protein phosphatase which binds to a very similar binding site of CaM as described above, but achieves it using a strikingly different architecture. In a 2:2 complex, CaM displays a native-like extended conformation while the calcineurin binding sequence is in alpha-helical conformation. However, the N-terminal lobe from one CaM and the C-terminal lobe from another form a combined binding site to trap the peptide, in a unique Xshaped arrangement [43, 44] . The binding sites thus created are quite similar to that of the most commonly seen bent complexes. Hydrophobic interaction between Val and Phe residues of the calcineurin segments and Met73 and Met77 of the neighboring CaM molecules rigidify their central helices, while a unique "electrostatic-knot" is bound by Arg residues from both calcineurins and Asp81 and Glu84 of CaM (see Fig. (5) ). These interactions are sufficient to stabilize the 2:2 complex in solution, too. This finding was reaffirmed in a molecular dynamics study, where it was shown that this surprising arrangement is stabilized by the ligand, and disassembles in absence of it [45] . Close contacting CaM residues in the calcineurin complexes are: Glu11/Glu14, Met72, Met 73, Met77, Asp81, Glu84, and Met144/Met145. Following an alternative activating mechanism the disordered substrate binding site of the target protein is actually assembled by its complexation with CaM -residues previously solvent exposed are brought into proximity while CaM itself is engulfed by the protein in an extended conformation. Bacillus anthracis anthrax adenyl cyclase exotoxin behaves accordingly [46] . A strong, nanomolar scale interaction is formed between the edema factor of the toxin and CaM. Analyzing the different crystal structures available describing this complex [47] [48] [49] [50] , the consensus set of CaM residues forming the interaction are both acidic amino acids and members of the terminal hydrophobic patches: Glu11, Glu14, Phe19, Ser38, Glu87, Arg90, Lys94, His107, Leu112, Glu114, Met124, Asp131, Met145.
The binding event itself appears to be a multi-step process, mediated by electrostatic interaction of the positive charge of a Lys that is exposed in the CaM-free state of the toxin which forms a favorable electrostatic interaction with the negative charge of CaM. Interestingly, the CaM-binding sequence of the edema factor contains a 1-8-14
motif, but these residues do not interact with CaM, showing how difficult it is to pinpoint CaM binding sequences or to predict the type of interaction between CaM and its targets in absence of structural information.
Another adenyl cyclase toxin from Bordatella pertussis, the etiologic agent of whooping cough, was also co-crystallized with the C-teminal domain of CaM, where a very similar set of CaM residues coordinated it [51] .
However, in case of the anthrax toxin a Leu, while in the complex formed with the Bordatella pertussis toxin, a Trp residue is hosted by the C-terminal characteristic hydrophobic pocket. Molecular dynamics simulations of the fulllength CaM-Bordatella pertussis toxin complex supported by mutagenesis and functional studies revealed that the toxin interacts with the N-terminal Ca
2+
-binding domains of CaM differently from anthrax edema factor, in spite of their high structural similarity [52] .
Apo-CaM (Ca 2+ -free CaM) can also complex a number of targets. The CaM binding region of these proteins usually contains an IQ motif. This motif consists of the IQXXXRGXXXR sequence or some close variant of it, which appears once or in tandem within the target sequence [41] . Unconventional myosin V forms such a complex in absence of Ca 2+ in folded, inactive conformation, where all six of its IQ motifs bind the extended apo-CaM. The crystal structure with one IQ peptide bound to the C-terminal domain of apo-CaM shows the peptide bound by a shallow hydrophobic groove lined by Phe92, Leu105, Met124, Ala128, Phe141 and Met144. A similar set of residues forms the deep hydrophobic pocket in Ca 2+ -loaded CaM, but the orientation of the F and G helices is different in the semi open conformation of the Ca 2+ -free state. Other CaM residues participating in the interaction are Glu11, Glu14, Asn42, Met109, Lys115, Glu123, and Glu127. This conformation cannot bind Ca 2+ tightly, since the chelating residues are misoriented, which has implications for the activity of the enzyme. At low Ca 2+ concentration a transformation to the unfolded, active state takes place, while high Ca 2+ concentrations cause inactivity due to CaM dissociating from one or more of the IQ motifs [53] . A similar effect can be seen in the case of CaM interacting with voltage gated calcium channel CaV1.2. In the initial phase of the interaction apoCaM binds to the IQ motif of the CaM binding region. This association is necessary for the rapid binding of Ca 2+ to C-terminal
CaM, which in turn results in the release of IQ. Following this the C-lobe engages another region, resulting in the Ca 2+ -dependent inactivation of the channel [54] .
CaM is also a modulator of caldesmon, a regulator of smooth muscle contractions. Most likely, CaM binds to caldesmon in an extended conformation [55] . The Trp residues of caldesmon play key role in the association.
Mutagenesis and fluorescence titration results suggest a great degree of flexibility in the interaction. Native binding can be disrupted and alternative spatial arrangements achieved [56] .
CaM, in complex with the binding domain peptide of HIV-1 matrix protein p17 also forms an extended structure. The peculiarity of this complex is that it is stabilized by electrostatic interactions instead of the hydrophobic complementary seen in most CaM-target complexes. Glu47, Asp50, Asp56 of the N-terminal, Glu139
of the C-terminal domain participate in ligation, but most significantly Glu67, Arg74, Asp78, and Glu82 of the flexible linker between the two [57] . Aquaporin-0 (AQP0) is expressed in the eye lens, where its water permeability is regulated by CaM. Two molecules of CaM bind the AQP0 tetramer C-terminal domain in a calcium-dependent manner in a noncanonical fashion. The binding mode suggests that CaM may be inhibitory to channel permeability by capping the vestibules of two monomers within the AQP0 tetramer. Phosphorylation within AQP0's CaM binding domain inhibits the AQP0/CaM interaction, suggesting a temporal regulatory mechanism for complex formation [59] . Mutation experiments provide support for these findings demonstrating that phosphorylation determines the calmodulinmediated Ca2+ response and water permeability of AQP0 [60] .
Even terminal residues of both the target and CaM can induce drastic changes in the complex formed between the two. Myristoylation of terminal residues of a nonapeptide from neuro-specific protein CAP-23/NAP-22 was shown to play an important role; it determines whether a compact globular complex is formed in the interaction with CaM [61] . On the other hand, deletion of the N-terminal leader sequence of CaM alters its interaction with myosin light chain kinase, one of the classical examples of "wrap-around" globular complex formation. If residues 1-8 are missing from the sequence of CaM, in the complex it will block the catalytic cleft of the kinase, instead of exposing it, as expected in case of the auto-inhibitory domain activation mechanism seen in the intact proteincomplex [62] .
Based on the bounty of complexation-modes discovered, it seems that for CaM practically everything is possible due to its plasticity, which leaves one with the overwhelming question of how is, with such a simple and pliable apparatus, specificity and selectivity achieved.
CAM AND CALCIUM
CaM in itself binds Ca 2+ tightly and cooperatively, first to the higher affinity sites of the C-terminal domain and then the two sites of the N-terminal domain [63, 64] . However, in the presence of targets, Ca 2+ binding becomes cooperative for all four sites, relative affinity of the sites changes, might even be reversed, while the absolute affinity of the sites might drastically increase in some cases, and diminish in others [58, 65, 66] . On the other hand, in contrast to the initial picture of CaM function, a new model evolved considering that target binding can take place in the apo, or partially Ca 2+ -loaded states, too, which in turn profoundly alters the calcium affinity and conformational flexibility of CaM [5, [67] [68] [69] [70] [71] [72] [73] [74] [75] . Direct evidence supports that Ca 2+ binding can be uncoupled from conformational change of CaM through the binding of effectors [76, 77] .
CaM interacting with Bacillus anthracis anthrax adenyl cyclase exotoxin presents such an example. The binding event takes place in at least two steps. The association is initiated by the Ca , already a weak interaction between N-CaM and the edema factor of the toxin is formed. Binding of Ca 2+ to C-CaM renders the interaction stronger while Nterminal domain exhibits strongly reduced Ca 2+ affinity [65] . Crystallization provided an explanation for this.
Interaction with the helical region of edema factor locks the N terminal domain of CaM into a closed conformation independent of its Ca 2+ -loaded state. Even at elevated Ca 2+ levels, when Ca 2+ binds to the distorted sites missing one or two of the Ca 2+ coordinating residues, the transformation to open conformation does not take place:
conformational switch is uncoupled from Ca 2+ binding [50] . These findings were also confirmed by molecular dynamics simulations of the complex, where the form with two Ca 2+ -ions bound to the C-terminal domain of CaM resulted in maintaining the active conformation of the edema factor, while the complex formed with 4Ca 2+ -CaM or apo-CaM lead to instability -the unwinding of the central liker of CaM and the collapse of the edema-factor binding site [66] . Quite the opposite takes place in case of the Ca 2+ activated K + channel, where the C-terminal lobe of CaM is locked into Ca 2+ -free, partially open state by the association [58] .
The presence of apo-CaM is essential for cell survival [67] , and it is now certain that some enzymes (inducible nitric oxide synthase [68] , cyclic nucleotide phosphodiesterase [69, 70] , glycogen phosphorylase [71] , brush border myosin I [72] , and neuronal proteins such as neuromodulins [73] , neurogranin [74] and PEP19 [75] ) actually prefer interacting with this form of CaM [5] . Furthermore, PEP-19, neurogranin and neuromodulin, has been noted to enhance dissociation of Ca 2+ from calmodulin they seem to represent the machinery of neurons to regulate CaM activation in addition to limiting calcium availability [75] . give rise to the characteristically distinct behavior of CaM toward its variety of targets.
CAM AND SMALL MOLECULES
The extreme variability of binding of protein targets implies that small-molecule ligands may be accommodated at a variety of sites on the CaM surface. The modulatory action of this protein is inhibited by trifluoperazine (TFP), a small molecule (Fig. (7) A), which competes with target proteins for CaM binding. TFP belongs to typical antipsychotics used basically in the treatment of schizophrenia. Cook et al. determined the crystal structure of the 1:1 complex and found that the central α-helix becomes distorted and the N-and C-terminal domains get in close vicinity, like in most complexes of CaM with its targets [13] . The TFP molecule makes extensive, but not specific contacts with residues in the C-terminal domain and practically none with the N-terminal domain. The structure suggests that substrate binding to the C-terminal domain is sufficient to cause the conformational changes in CaM leading to the activation of its targets. It has been thought that the binding of the first TFP molecule to the Cdomain is followed by binding of the second one to the N-domain. The crystal structure of the 1:2 CaM-TFP complex proves, however, that binding of a TFP molecule to the C-terminal hydrophobic pocket (involving residues Leu105, Ala128, Met124 and Met144) is followed by the interaction of the second one with an interdomain site [80, 81] , where Glu14, Glu114
and Glu120 participate in the coordination of its positive charge, and Met124 interacts with its phenothiazine moiety.
It has been shown that the central linker region of the protein is indispensable for simultaneous interactions with two TFP molecules. In the 1:4 complex, TFP1, TFP2 and TFP3 are bound to the C-terminal lobe, while TFP4 to the Nterminal lobe (see Fig. (8) ). Both hydrophobic (Val55, Il63, Met71, Met109, Leu116, Met124, Met145) and acidic (Glu11, Glu54, Glu114, Glu120) residues of CaM participate in the complexation. The tertiary structure of CaM changes from an elongated dumb-bell, with exposed hydrophobic surfaces, to a compact globular form upon TFP ligation which hinders its interaction with target proteins [14, 82] . In order to clarify the strength of interaction between CaM and TFP in solution, Yamaotsu et al. [83] performed a molecular dynamics simulation of the CaM-TFP complex in aqueous solution starting from the crystal structure of the 1:4 complex. The obtained solution structure is very similar to the structure of the 1:2 complex. The computer simulation showed that the binding ability of the secondary binding site of the C-domain is higher than that of the primary binding site of the N-domain. residue peptide that mimics the targets of CaM and binds to it with nanomolar affinity. It was a rather surprising finding, that instead of displacing melittin from the complex, two molecules of TFP were able to bind to it, forming a melittin-TFP 2 -CaM arrangement. CD spectroscopic studies of this ternary complex revealed that the two molecules of TFP are probably bound to inter-domain sites that are different from those previously detected, stressing again the role of the central linker region in fine tuning CaM's interactions [81] .
TFP was also shown to bind Ca 2+ -free CaM, and cause conformational rearrangement of it to an overall ellipsoid shape. This interaction most likely involves inter-and intra-domain binding sites, and still another mode of TFP accommodation by CaM [82] . The non-specific nature of TFP ligation to CaM was also underlined by molecular dynamics simulation of the CaM : 2TFP complex, where it was shown, that the surface close ionic attraction between Glu residues of CaM and the positive charge of the piperazine ring of each TFP molecule looses its significance when solvation is introduced and the surface close acidic residues can interact with water instead of the delocalized charge of TFP. This then leaves TFP greater conformational freedom within the hydrophobic interior of the complex [84] .
The solution structure of the N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W7)-CaM complex (see W7 in Fig. (7) B) has been determined by multidimensional NMR spectroscopy [85, 86] . The structure contains two molecules of the inhibitor, each binding competitively to the N-and C-terminal domain of the protein. It is quite interesting to see that both the elongated, dumbbell shape and the compact, globular form appears among the solutions, with both the N-and the C-terminal hydrophobic patches are occupied. The two bound molecules interact with independent binding sites, no interdomain site is formed, and the terminal lobes freely rotate with respect to one-another [85] (see Fig. (9) ). Small angle X-ray scattering results argue in favor of the compact globular shape [86] , indicating again, the great plasticity of the CaM backbone. According to the NMR structure, the chloronaphthalene ring interacts with methionine side chains and other aliphatic or aromatic side chains in the deep hydrophobic pockets of the terminal lobes of CaM. The orientation of the W7 naphthalene ring in the N-terminal pocket is rotated to a certain extent with respect to that in the C-terminal pocket, however the residues forming the binding sites are quite similar, Phe19/Phe92, Leu32/Leu105, Met51/Ile125, Ile52/Ala128, Ile63/Val136, Phe68/Phe141, Met72/Met144-Met145 in the N-terminal/C-terminal domains, respectively. The role of the four Phe residues seems to be the shielding of the chloronaphthalene ring from the polar backbone atoms of each lobe.
Although the W7 ring orientation differs significantly from that of the Trp800 indole ring of chicken smooth muscle [87, 88] , it has been demonstrated that complex formation between CaM and melatonin prevents the activation of neuronal nitric oxide synthase [89] , and plays an important role in mediating the growth-inhibitory effect in cancer cells [90] . Binding conformation of melatonin to CaM was studied by fluorescence and NMR spectroscopic experiments and by molecular dynamics simulations [2] . Both experimental and MD results indicate that the calcium-dependent interaction of melatonin with CaM is significant but weak.
Since melatonin is quite similar to the Trp residue, it might not be so surprising that its indole ring binds to the Trp 3`-(β-chloroethyl)-2`,4`-dioxo-3,5`-spiro-oxazolidino-4-deacetoxyvinblastine (KAR-2; Fig. (7)F) , a semisynthetic bisindole alkaloid is a potent anti-microtubular agent that arrests mitosis in cancer cells without significant toxic side effects. It has been demonstrated that KAR-2 also binds to CaM, somewhat neutralizing the antagonistic effects of TFP. Crystal structure determination of KAR-2 was partially triggered by the curious observations that this drug molecule is able to bind to the CaM-TFP complex without displacing TFP from it [80] , and that, in spite of the fact that it does interact with CaM, does not affect the protein's action on 1-phosphofructokinase [91] and is unable, at any concentration, to decrease CaM dependent phosphodiesterase activity below 50% [81] . Accordingly, the crystal structure of the complex revealed a novel binding mode for this drug (see Fig. (9) ) while nuclear magnetic resonance spectroscopy indicated that solution structure of the complex is also consistent with the crystal structure [18] . Fig. (9) . The structure of the CaM-KAR-2 complex (pdb code:1xa5, [18] ).
The structure provided immediate explanation to this unique behavior. Ca 2+ loaded CaM binds KAR-2 in a compact, "wrap-around" conformation similar to that seen in its TFP or peptide complexes, however, the KAR-2 molecule is situated in an inter-domain position between the N-and C-terminal lobes, leaving the hydrophobic, intradomain clefts unoccupied. It only makes close contacts with Leu18, Leu39, Phe68 and Ile85, while its polarizable chlorine atom is loosely coordinated by Met109 and Glu114. Therefore, binding of KAR-2 pre-assembles the target binding, globular conformation of CaM, without competing for the most specific, hydrophobic binding sites.
Superimposition of the structures of the CaM-KAR-2 and CaM-TFP 1:1 complexes demonstrates that KAR-2 and the C-terminal bound TFP are accommodated in distinct sites. A surprising feature of the interface between KAR-2 and CaM is that the hydrophobic pockets are distorted by the drug binding. This conformational change induces a limited inhibitory effect on CaM mediated events [18] .
Vinblastine ( Figure 7G ), the mother compound of KAR-2, in contrast, is a competitive inhibitor, its interaction with CaM is completely abolished by the presence of TFP. It is, however, able to bind in the presence of KAR-2, although the two drugs mutually weaken each-other's binding, which suggests that they interact with distinct, but partially overlapping sites. This is made significant by the fact that the structures of KAR-2 and vinblastine are very similar, in fact, identical in the catharantine part, with a difference of only a few atoms of the vindoline moiety, where KAR-2 carries a substituted oxazolidino ring, closed across the two C-3 substituents. Data suggest that, while vinblastine, devoid of this five-membered ring, is able to fit in the hydrophobic groove of the Cterminal lobe of CaM, KAR-2 is no longer able, due to the presence of it [81] .
Binding with a further antagonist N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide (J8; Fig. (10) A) was investigated by NMR spectroscopy by Craven et al. [15] . It has been shown that the primary interaction between J8
and CaM is between the naphthalene ring of the former and the hydrophobic pockets of the protein (Phe92 and Phe141 implicated in the interaction with the C-terminal region) resulting in a 2:1 (J8: CaM) complex, similar to the binding of the hydrophobic side-chain residues of calmodulin target peptides. It was found that the aliphatic amino group of the ligand is highly mobile, and it forms no or only weak interaction with the protein.
A further type of CaM antagonists is
propylene-diamine (AAA; Fig. (10)B) , which also forms a 1:2 complex with the protein, binding both to the N-and C-terminal pockets [17] in a very similar orientation (see Fig. (4) ). equivalent with the inter-domain ones, may be present in the complex. The structure of the complex was independently determined from two crystals belonging to different space groups. It is interesting to note, that while the accommodation of the diphenylpropyl moiety of AAA was quite similar in both cases, due to the differences in the tertiary structure of CaM, the 3,4-bis-butoxyphenyl coordination was achieved in a variety of different modes.
The differences in the backbone structure of CaM determined from the two different crystals is the degree of its domain closure, which also shows how subtle changes are sufficient (in this case, a change in crystal packing forces)
to create markedly different arrangements of this highly flexible molecule.
Using a thioether substituted arylamide scaffold, highly specific CaM inhibitors were designed that also showed nanomolar inhibitory effect. The most successful molecule is capped with D-Phe group at each end to withstand proteolysis, and is equipped with flexible amine sidechains to facilitate interaction with the acidic residues of CaM (see Fig. (10)C) . Arylamide derivatives mimic membrane binding helical peptides [92] and are thought to bind to CaM in a similar way to that of smooth muscle myosin light chain kinase based on 2D ( CaM is a highly acidic protein, therefore small molecule ligands possessing both hydrophobic and positively polarized moieties would be expected to coordinate to it with ease. However, antagonists with net positive charge (trifluoroperazin for example) or easily polarized heteroatoms (like W7 or KAR-2) form only few, non-specific ionic interactions with it. This might be because the negatively charged amino acids of CaM tend to be surrounded by bulky hydrophobic residues which shield them from straightforward electrostatic contacts -for example, along
Glu11 we find Phe12, by Glu14, Ala15 and Leu18 and the through-space neighbor of Glu120 is Leu116. That the Glu and Asp residues of CaM are indeed difficult to reach is reflected by the structure of the peptide complexes of the protein. In 13 selected structures representing a wide array of different binding arrangements [46, 48, 49, [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] , 53 H-bond contacts (with heteroatom distance within 3.5 Å) between negatively charged amino acids of CaM and its complexed peptides were identified. In 85% of the cases, the interacting partner was a Lys or an Arg residue, and in only 8 cases did other possible proton donors, such as Thr, His, Ser, Asn and Gln take part in the interactions.
In the 13 complexes analyzed, in only one case was the carboxylate group of a CaM residue coordinated by backbone amide nitrogen of the target peptide [84] . This demonstrates that the negative charge centers of CaM prefer interacting with such molecular segments where an isolated positive charge is located at the end of a long, flexible aliphatic chain. Successful candidates should therefore contain hydrophobic anchors and positively polarizable groups at the end of a long tether -such as the D-Phe substituted arylamide molecule, which did show nanomolar inhibitory effect [93] (see Fig. (10)C) .
However, strong binding does not insure selectivity in case of CaM. A significant overlap in interacting residues can be seen in spite of the varying degree of domain closure upon complexation, due to the fact that the terminal lobes function as independent sites as well. Glu11 is the gatekeeper, it comes into contact with practically anything ligated, although the surface-close electrostatic interactions it forms are probably more significant in the crystal structures than in the physiological, solvated states [83] . Glu14, Phe19, Met71, Met72 of the N-terminal and Glu114, Met124, Met144 of the C-terminal domains are commonly appearing partners of different ligands, while
Glu84 and Glu87 of the central linker form several H-bond interactions too. However, specificity can also be found.
For example, in case of the edema factor of Bacillus anthracis anthrax adenyl cyclase, Ser38 and Arg90 of CaM, which are both outside the canonical set, form strong H-bonds with a Ser and an Asp residue of the target, respectively [46, 50] . Disrupting these interactions would possibly destabilize the complex, while leaving the most commonly used binding spots free for coordination of other targets. KAR-2 is a nice example of selectivity achieved in this fashion. With this potent anti-microtubular agent bound to the interdomain site of the globular form, CaM retains its 1-phosphofructokinase and phosphodiesterase activating capacity [81, 91] . On the other hand, "classical"
CaM antagonists, binding to the hydrophobic patches of the terminal lobes, such as TFP and W7, do not inhibit the activity of intermediate Ca 2+ activated K + channels [105] , in spite of the fact, that Ca 2+ -CaM-induced conformational changes are necessary for the channel opening [106, 107] , therefore CaM participation in the activation process is un-debatable. Thus, specific pharmacophore design should not be impossible.
Computer-aided studies of CaM and its interaction with ligands look back on a long history, however, taking into consideration the significance of CaM, such studies are surprisingly few. Prior to the determination of the crystal structure of CaM, a model of it was built based on the structure of troponin-C. Trifluoperazine binding was studied, predicting its ligation to an interdomain site of the elongated protein [108] . In another pioneering study, following the crystal structure determination of the Ca 2+ -loaded, open form of CaM [29] , tamoxifen binding was studied and optimized. Ligand binding to the independent C-terminal hydrophobic cleft was supposed, disregarding the possibilities of the bending of the central linker region or the association of the terminal lobes. Optimization of the molecular structure took place within this framework by energy-minimization calculations, which, combined with functional studies lead to the discovery of compounds showing micromolar IC 50 values in the antagonism of calmodulin-dependent activity of cAMP phosphodiesterase. Also, a correlation was found between CaM antagonism and cytotoxicity against MCF-7 breast tumor cells in vitro [109] .
Molecular dynamics studies have successfully complemented structural analysis and aided interpretation of the results in a number of cases [2, 32, 33, 45, 52, 66, 83, 84, 110] .
QSAR methodology was also applied to CaM. Liu and coworkers classified 24 calmodulin inhibitors into three groups (groups I, II and III), Using discriminant analysis they developed discriminant functions that distinguished between the groups in terms of positive potential surface area on the side chain, as well as the total and neutral surface areas on the ring in the inhibitor molecules. The results of their QSAR analysis showed that hydrophobicity was important for the ring moiety but not for the side chain, which should contain the nitrogen atom far from the ring moiety [111] . In another study QSAR methodology was applied to the characterization of diphenylalkylamines implicated in the antagonistic effect of CaM toward CaM-stimulated phosphodiesterase. Chain length, the presence or absence of the methyl group vicinal to the nitrogen atom, the methylation of the nitrogen atom as well as the presence of the oxygen as heteroatom in combination with benzhydryl substitution have been indicated as the most important molecular descriptors [112] Due to the diverse biological role of CaM, its antagonists showed significant promise for the pharma industry, initiating drug design research in the mid 90s. Several companies including Novartis, Akzo-Nobel, Takeda by Gebro Pharma and Novartis [113] and was licensed to Kyowa Hakko that investigated the compound in a phase 3
antidiarrheal trial in Japan. Unfortunately this late phase trial was reported to be discontinued in 2000 [114] .
Fig. (11). CaM antagonists in clinical and preclinical development
The other clinically investigated CaM antagonist is DY-9760 (see Fig. (11) Compounds, which reached the preclinical development represent five different chemotypes. Takeda reported imidazopyridines as CaM antagonists (see Fig. (11)C) [116]. Mitsubishi Tanabe identified dually acting tetrahydro-benzothiepine type CaM inhibitors (see Fig. (11)D) with calcium channel blocking activity for the treatment of hypertension and angina pectoris [117] . The company also described the pure CaM inhibitor TI-233
[114] as a development candidate for coagulation disorders therapy particularly for the treatment of thrombosis (see Fig. (11)E) , however, no active development was reported.
Akzo-Nobel filed one patent application [118] claiming bis-phenyl-methylthio-ethyl-phenylethylamines as calmodulin antagonists against angina pectoris (see Fig. (11)F) . Banyu described W-7 as potent and selective CaM antagonist (see Fig. (7) B) in two patent applications [119] . The compound is in preclinical development; however, no further progress has been reported.
In conclusion, the development data available for calmodulin antagonists in different indications suggest that the complex physiological role of this enzyme make drug development difficult. Although the structure of the enzyme has been available for more than 20 years and a number of potent and selective calmodulin antagonists have been identified up to now no pharmacotherapy related to this single mechanism was reported. We think that calmodulin antagonism as monotherapy might be less suitable for medical intervention. In combination with other mechanism or more importantly targeting specific CaM mediated pathophysiological processes might convert the already accumulated biochemical and structural biology knowledge to therapeutic value.
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